TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03558724

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Molecular Fluorescence Endoscopy platform
Description: A flexible fluorescence fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals. The fluorescence fiber-probe is inserted through the standard working channel of the standard clinical endoscope. Fluorescence imaging will be performed prior to and post the chemoradiotherapy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Molecular Fluorescence Endoscopy platform
Description: A flexible fluorescence fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals. The fluorescence fiber-probe is inserted through the standard working channel of the standard clinical endoscope. Fluorescence imaging will be performed prior to and post the chemoradiotherapy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Molecular Fluorescence Endoscopy platform
Description: A flexible fluorescence fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals. The fluorescence fiber-probe is inserted through the standard working channel of the standard clinical endoscope. Fluorescence imaging will be performed prior to and post the chemoradiotherapy.
Study: NCT03276143

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: 40 mg enoxaparin administered as subcutaneous injection once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban
Description: 2.5 mg apixaban administered as tablet orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1213790
Description: Single dose of BAY1213790 administered as intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1213790
Description: Single dose of BAY1213790 administered as intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1213790
Description: Single dose of BAY1213790 administered as intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1213790
Description: Single dose of BAY1213790 administered as intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1213790
Description: Single dose of BAY1213790 administered as intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1213790
Description: Single dose of BAY1213790 administered as intravenous infusion
Study: NCT02811107

Intervention type: OTHER
Intervention: Questionnaires
Description: Completion of questionnaires on tablet computers in the preoperative area by 6 nurse anesthetists, 1 hospital physician and 1 resident physician.
Study: NCT00704353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Carboxymaltose
Description: 15 mg/kg up to a maximum of 750 mg at 100 mg/minute intravenously on Day 0.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Care (SMC)
Description: Per product label
Study: NCT01454284

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glargine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2605541

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro
Study: NCT01814085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Escitalopram tablets will be administered orally in the dose range of 10 to 20 milligram per day (mg/day) for 8 weeks. Dose can be adjusted as per Investigator's discretion depending on participant's response.
Study: NCT00861406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon-Alfa 2b (PEG Intron)
Description: Group 1:~6 mcg/kg by injection under skin once weekly for 4 weeks, followed by Maintenance Phase of 3 mcg/kg weekly for 20 weeks.~Group 2:~6 mcg/kg by injection under skin once weekly for 8 weeks, followed by Maintenance Phase of 3 mcg/kg weekly for 16 weeks.~Group 3:~6 mcg/kg by injection under skin once weekly for 12 weeks followed by Maintenance Phase of 3 mcg/kg weekly for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon-Alfa 2b (PEG Intron)
Description: Group 1:~6 mcg/kg by injection under skin once weekly for 4 weeks, followed by Maintenance Phase of 3 mcg/kg weekly for 20 weeks.~Group 2:~6 mcg/kg by injection under skin once weekly for 8 weeks, followed by Maintenance Phase of 3 mcg/kg weekly for 16 weeks.~Group 3:~6 mcg/kg by injection under skin once weekly for 12 weeks followed by Maintenance Phase of 3 mcg/kg weekly for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon-Alfa 2b (PEG Intron)
Description: Group 1:~6 mcg/kg by injection under skin once weekly for 4 weeks, followed by Maintenance Phase of 3 mcg/kg weekly for 20 weeks.~Group 2:~6 mcg/kg by injection under skin once weekly for 8 weeks, followed by Maintenance Phase of 3 mcg/kg weekly for 16 weeks.~Group 3:~6 mcg/kg by injection under skin once weekly for 12 weeks followed by Maintenance Phase of 3 mcg/kg weekly for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP-100 Peptide Vaccine
Description: Injection under skin once every 3 weeks (Weeks 1, 4, 7, 10, 13, 16, 19, and 22), for a total of 8 injections.
Study: NCT01193335

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 13-valent pneumococcal conjugate vaccine
Description: 13-valent pneumococcal conjugate vaccine will be administered at 2, 3, 4 and 12 months of age.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 13-valent pneumococcal conjugate vaccine
Description: 13-valent pneumococcal conjugate vaccine will be administered at 2, 3, 4 and 12 months of age.
Study: NCT04637867

Intervention type: OTHER
Group type: OTHER
Intervention: Collection of blood, salivary and nasopharyngeal samples.
Description: Each visit M6 and M12~* Blood: 1 PAXgene tube (2.5mL) 1 EDTA tube (4mL), 1 dry tube with gel (5mL), 3 EDTA tubes (10mL each)~* Salivary sample~* Nasopharyngeal sample
Study: NCT01018407

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Discrete Trial Training
Description: UCLA model, developed by Lovaas and colleagues (Smith, Groen \& Wynn, 2000). Two 30-minute sessions daily (5 hours/week) of 1:1 intervention focusing on imitation, match-to-sample, receptive and expressive language. Using operant conditioning, the therapist works individually with a child in a distraction-free setting and administers approximately 10 trials in a sitting, with breaks between sittings.~During months 5 and 6, we will provide parents with training in an apprenticeship format one day per week for an hour per day. The clinician will demonstrate a DTT instructional program, then the parent will take a turn implementing it. The clinician and parent will give each other feedback on their implementation of the program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Developmental Approach
Description: Focus on teaching joint attention and symbolic play developmentally via floor play milieu teaching approach. Principles applied include following the child's lead and interest in activities, talking about what the child is doing, repeating back what the child says, expanding on what child says, giving corrective feedback, sitting close to the child and making eye-contact, and making environmental adjustments to engage the child (Kasari et al., 2006).~Parents will be incorporated into the treatment to encourage joint engagement with their child and to focus specifically on joint attention and play skills in their interactions. Each home session will last one hour (once a week) during month 5 and 6 and will involve therapist modeling, and coaching of parent in child-directed activities.
Study: NCT02126488

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: treadmill slip perturbation
Description: Group A will receive perturbation training on a treadmill with precisely controlled slip-like displacements and then encounter an unannounced novel slip during over-ground walking.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: treadmill training placebo
Description: An age-matched control group (Group B) will receive only placebo training (on the same treadmill for the same duration but without perturbation) but encounter an identical novel slip during their over-ground walking.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: observation training
Description: An age-matched observation-training group (Group C) will watch a training video and slides. When exposed to an identical novel slip in over-ground walking, they will know where and how the slip is going to occur and how to resist a fall.
Study: NCT03192904

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Energy Instruments
Description: Energy Instruments, including electrocautery, harmonic scalpel and LigaSure.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stapling Device
Description: Stapling Device, including linear stapler and curved stapler.
Study: NCT01938287

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SENSIMED Triggerfish
Study: NCT02814721

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sonic Window ultrasound device
Study: NCT04846114

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental implant surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dental implant surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental implant surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental implant surgery
Study: NCT03588689

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous fascia iliaca block
Description: Regional nerve block performed under ultrasound guidance. A catheter will be left in place to allow ongoing infusion of local anesthetic.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Ropivacaine local anesthetic will be used for the fascia iliaca block
Study: NCT00158366

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral training
Description: The behavioral training will teach participants ways to control their diet and increase their physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral training
Description: The behavioral training will teach participants ways to control their diet and increase their physical activity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social skills training
Description: The social skills training will teach participants how to indirectly control their weight by making social contacts and seeking social support.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral training booster sessions
Description: During biweekly booster treatment sessions, participants will discuss their response to different diet and exercise regimens, and researchers will discuss strategies for increasing one's success with the regimens.
Study: NCT00384579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin B
Description: Botulinum Toxin B
Study: NCT00861406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP-100 Peptide Vaccine
Description: Injection under skin once every 3 weeks (Weeks 1, 4, 7, 10, 13, 16, 19, and 22), for a total of 8 injections.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP-100 Peptide Vaccine
Description: Injection under skin once every 3 weeks (Weeks 1, 4, 7, 10, 13, 16, 19, and 22), for a total of 8 injections.
Study: NCT01149473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan potassium/Hydrochlorothiazide
Description: 100/25 mg Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan potassium/Hydrochlorothiazide
Description: 100/25 mg Tablets
Study: NCT01963806

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smartphone-supplemented iCBT
Description: The Internet-administered cognitive behavioural self-help program (iCBT) will be divided into 10 weekly, progressively available modules covering CBT and Acceptance and Commitment Therapy (ACT) conceptualisations of anxiety disorders, as well as more specific therapeutic techniques such as cognitive restructuring, exposure training, attention and breathing exercises and relapse prevention . Each module also includes writing exercises.~Also included is a tailored smartphone application. Briefly, the application allows the user to access, create and modify a personal database of behaviours and check-off these behaviours immediately when completed. Frequency of carried-out behaviours are recorded and displayed as statistics. The application also allows users to browse and search a database of behaviours uploaded by other study participants, providing both inspiration and a sense of social support.
Study: NCT04457284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide (TMZ)
Description: TMZ 150 mg/m2 Day 1 - 5 Q4W PO Cycle 1~TMZ 200 mg/m2 Day 1 - 5 Q4W PO Cycle 2 +

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 40 mg/m2 Q2W IV infusion Cycle 1 +

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 480 mg Q4W IV infusion Cycle 1 +
Study: NCT00384579

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03689595

Intervention type: OTHER
Intervention: Sample of Blood
Description: Collection of blood sample from participants
Study: NCT03347435

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: genetic tests for CYP2C19*2, CYP2C19*17 and ABCB1 3435
Description: The CYP2C19\*2 (10q24.1-q24.3; rs4244285), CYP2C19\*17 (10q24.1-q24.3; rs12248560) and ABCB1 3435 (7q21.1; rs1045642) genetic variants will be genotyped using an ST Q3 system. The conventional genotyping methods so far used for diagnostic purposes will not be used in this study because appropriate labs may not be readily available and the processing time is prohibitive. Q3 is a compact platform enabling the classical laboratory analysis of DNA by means of real-time PCR. The Q3 has been designed as a low entry-cost, portable, point-of-care instrument for foolproof use by unskilled personnel. Antiplatelet therapy will be choose on the basis of clinical and genetic algorithm.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: clinical algorithm
Description: Antiplatelet therapy will be choose on the basis of clinical algorithm alone
Study: NCT03663179

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: A MagPro R30 (Magventure, Inc., Copenhagen, Denmark) device with a Cool-B65 A/P figure 8 coil will be used to deliver TMS. This coil has an active side and a sham side, and can be used to perform double-blinded studies. TMS will be administered at 10 Hertz (Hz) with an intensity of 120% of patient resting motor threshold. Stimulation will be delivered to the left dorsolateral prefrontal cortex using 20 sec cycles (i.e., 5 sec train with 15 sec inter train interval). Subjects will receive 80 trains per session for a total of 4000 pulses per session (\~26 min sessions). Twenty sessions will be completed on sequential weekdays (5 days per week for 4 weeks).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Magnetic Stimulation (Sham TMS)
Description: A MagPro R30 (Magventure, Inc., Copenhagen, Denmark) device with a Cool-B65 A/P figure 8 coil will be used to deliver TMS. This coil has an active side and a sham side, and can be used to perform double-blinded studies. For sham stimulation, the sham side of the coil is positioned toward the participant's scalp. The sham coil is designed to mimic the appearance and sound of active TMS stimulation, but is equipped with a magnetic shield that reduces the strength of the field by approximately 80%. This reduction in field strength ensures that no neural stimulation occurs. Twenty sessions will be completed on sequential weekdays (5 days per week for 4 weeks).
Study: NCT01134094

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open reduction internal fixation of the ankle
Description: The specific procedure for each patient managed operatively, both in the observational study and the RCT, will be determined by the operating surgeon. Any adverse intra-operative or post-operative event will be recorded. This includes but is not limited to death, infection and neurovascular injury. Post operatively, all patients will be NWB (non weight bearing) and placed in a POP (plaster of paris) below knee cast or walking boot. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. The treating surgeon will review the patients after 10-14 days for a wound review, removal of sutures and change of cast to a fibreglass cast or walking boot (cam walker). The patient will be WBAT (weight bearing as tolerated) for a further 4 weeks.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non Operative
Description: Patients who are treated non-operatively will be treated with a walking boot and allowed WBAT. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. All patients will be reviewed between 7 and 14 days post injury with repeat x-rays by the treating surgeon.
Study: NCT04327453

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: double antibiotic paste with XP-endo Finisher file
Description: XP-endo Finisher files (FKG Dentaire, La Chaux-de-Fonds, Switzerland). file will be used with an endodontic motor X-Smart (Dentsply Sirona, Ballaigues, Switzerland) in removal of double antibiotic paste

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: double antibiotic paste with Irrisafe Ultrasonic tip
Description: passive ultrasonic irrigation (PUI) with an IrriSafe Ultrasonic tips (Acteon,France), which will be driven by an ultrasonic device (Newtron P5, Satelec, Acteongroup, Merignac, France) in removal of double antibiotic paste

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: double antibiotic paste with side vented needle
Description: conventional syringe irrigation with side vented needle (prime Dent, India) in removal of double antibiotic paste
Study: NCT02645409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTL38
Description: OTL38 is a folate analog conjugated with a fluorescent dye that emits light in the near infrared spectrum. This longer wavelength allows for deeper penetration of the fluorescent light through tissues with the potential to better image tumors beneath adipose tissue or deeper into organ parenchyma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTL38
Description: OTL38 is a folate analog conjugated with a fluorescent dye that emits light in the near infrared spectrum. This longer wavelength allows for deeper penetration of the fluorescent light through tissues with the potential to better image tumors beneath adipose tissue or deeper into organ parenchyma.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraoperative fluorescence imaging system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraoperative fluorescence imaging system
Study: NCT03617523

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone Quadrivalent vaccine, 2018-2019 formulation
Description: Pharmaceutical form: Suspension for injection Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone Quadrivalent vaccine, 2018-2019 formulation
Description: Pharmaceutical form: Suspension for injection Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone Quadrivalent vaccine, 2018-2019 formulation
Description: Pharmaceutical form: Suspension for injection Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Flublok Quadrivalent vaccine, 2018-2019 formulation
Description: Pharmaceutical form: Suspension for injection Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone High-Dose vaccine, 2018-2019 formulation
Description: Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
Study: NCT03427164

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transjugular Intrahepatic Portosystemic Shunt
Description: The TIPS procedures creates an artificial shunt from the portal vein to the hepatic vein. TIPS allows blood from the congested portal circulation to bypass the fibrotic liver and directly enter the systemic circulation.
Study: NCT00965185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: 20 mg PO QD for the first 3 months, followed by 40 mg PO QD for the final 9 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo